We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Regeneron Pharmaceuticals Jumped on Monday
Shares of Regeneron Pharmaceuticals (REGN - Free Report) surged higher on Monday as speculation grew that the FDA will authorize its coronavirus treatment for emergency use.
REGN closed up over 7% to $605.08 per share. The pharma stock has gained about 23% over the past six months
Regeneron’s treatment was given to President Trump over the weekend after he was taken to Walter Reed Medical Center following his Covid-19 diagnosis. Trump’s doctors said he received an infusion of the company’s dual antibody treatment.
The drug is known as REGN-COV2, and is currently being evaluated in a trial that is studying its use in early coronavirus infections.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>